Ozempic vs Mounjaro: Which GLP-1 Is Better?

For patients struggling with type 2 diabetes or obesity, GLP-1 receptor agonists like Ozempic and Mounjaro have revolutionized treatment. But which one is right for you? Ozempic (semaglutide) has been a trusted option for years, while Mounjaro (tirzepatide) is a newer dual-action drug showing even greater efficacy in clinical trials. This evidence-based comparison will help you understand the differences in weight loss, side effects, cost, and mechanism of action between Ozempic and Mounjaro.

Ozempic vs Mounjaro for Weight Loss

Both Ozempic and Mounjaro promote weight loss, but studies suggest Mounjaro may be more effective. In the SURMOUNT-1 trial, participants taking the highest dose of Mounjaro (15 mg) lost an average of 22.5% of body weight over 72 weeks, compared to 14.9% with Ozempic (2.4 mg) in the STEP 1 trial. The difference likely stems from Mounjaro’s dual action—it activates both GLP-1 and GIP receptors, enhancing satiety and metabolism more than Ozempic, which only targets GLP-1.

For patients with obesity (BMI ≥30) or weight-related complications, Mounjaro may be the superior choice. However, Ozempic remains a strong option for those with type 2 diabetes, as it also improves glycemic control. Both medications require lifestyle changes (diet, exercise) for optimal results.

Side Effects Compared

Ozempic and Mounjaro share similar side effects, primarily gastrointestinal (GI) issues like nausea, vomiting, diarrhea, and constipation. However, Mounjaro may cause slightly more GI discomfort due to its stronger mechanism. In clinical trials, ~20% of Mounjaro users reported nausea (vs. ~16% with Ozempic), while ~12% experienced diarrhea (vs. ~9% with Ozempic).

Both drugs can also cause:

• Hypoglycemia (low blood sugar, especially when combined with insulin or sulfonylureas)
• Pancreatitis (rare but serious)
• Gallbladder issues (due to rapid weight loss)

Mounjaro has an additional warning for thyroid C-cell tumors in animal studies, though human risk remains unclear. Patients with a history of medullary thyroid cancer or MEN 2 syndrome should avoid both drugs.

Cost: Ozempic vs Mounjaro

The cost of Ozempic and Mounjaro is a major consideration, as both are expensive without insurance. The list price for Ozempic is ~$900–$1,200 per month, while Mounjaro ranges from ~$1,000–$1,300 per month. However, real-world costs vary based on dosage, insurance coverage, and manufacturer savings programs.

• Ozempic has a patient assistance program (NovoCare) offering discounts for eligible individuals.
• Mounjaro (Eli Lilly) provides a savings card that can reduce costs to $25/month for commercially insured patients.

For uninsured patients, Ozempic may be slightly more accessible due to its longer market presence and generic alternatives (e.g., Wegovy, which is the same drug at a higher dose for weight loss).

How They Work Differently

Ozempic is a GLP-1 receptor agonist, meaning it mimics the hormone glucagon-like peptide-1 (GLP-1), which:

• Slows gastric emptying (reducing appetite)
• Enhances insulin secretion
• Suppresses glucagon (lowering blood sugar)

Mounjaro, however, is a dual GIP/GLP-1 receptor agonist. In addition to GLP-1 effects, it also activates glucose-dependent insulinotropic polypeptide (GIP), which:

• Further enhances insulin release
• May improve fat metabolism
• Potentially reduces food cravings more effectively

This dual mechanism explains why Mounjaro often leads to greater weight loss and blood sugar control than Ozempic. However, Ozempic has a longer track record for safety and cardiovascular benefits.

Which Is Better?

The “better” drug depends on individual health goals:

• For weight loss alone: Mounjaro is likely superior due to its dual-action mechanism and greater efficacy in trials.
• For type 2 diabetes: Both are effective, but Ozempic has more long-term data supporting cardiovascular benefits.
• For tolerability: Ozempic may cause fewer GI side effects, making it a better choice for sensitive patients.

Patients with severe obesity (BMI ≥35) or weight-related comorbidities (e.g., fatty liver, sleep apnea) may benefit more from Mounjaro. Those with diabetes and heart disease may prefer Ozempic due to its proven cardiovascular safety.

Switching Between Ozempic and Mounjaro

Switching from Ozempic to Mounjaro (or vice versa) is possible but requires careful monitoring. Since Mounjaro is more potent, patients transitioning from Ozempic may experience increased side effects (nausea, vomiting) if starting at a high dose. A gradual approach is recommended:

1. Stop Ozempic and wait 1–2 weeks before starting Mounjaro at a low dose (2.5 mg).
2. Titrate Mounjaro slowly (increasing by 2.5–5 mg every 4 weeks) to minimize GI discomfort.
3. Monitor blood sugar closely, as Mounjaro may require insulin dose adjustments.

Conversely, switching from Mounjaro to Ozempic may lead to rebound hunger or weight gain, so a structured transition plan is essential.

Insurance Coverage Compared

Insurance coverage for Ozempic and Mounjaro varies by plan, but Ozempic is generally more widely covered for diabetes treatment. Mounjaro is newer, so some insurers classify it as a weight-loss drug, which may require prior authorization or higher copays.

• Medicare covers Ozempic for diabetes but not for weight loss alone.
• Medicaid coverage varies by state, with some plans covering Mounjaro only for diabetes.
• Private insurers may require documentation of failed weight-loss attempts before approving Mounjaro.

Patients should check with their insurer or use manufacturer savings programs to reduce out-of-pocket costs.

Frequently Asked Questions

Is Ozempic or Mounjaro better?

Mounjaro is generally more effective for weight loss, while Ozempic has a longer safety record for diabetes and heart health. The best choice depends on individual health goals and tolerability.

Can you switch from Ozempic to Mounjaro?

Yes, but it should be done gradually under medical supervision to avoid side effects. Starting Mounjaro at a low dose (2.5 mg) helps minimize nausea and GI discomfort.

Which has fewer side effects?

Ozempic tends to cause fewer GI side effects than Mounjaro, though individual responses vary. Both can cause nausea, vomiting, and diarrhea, especially at higher doses.

Disclaimer from Dr. Amanda Liu

This article provides general medical information and is not a substitute for professional advice. Always consult your healthcare provider before starting or switching medications like Ozempic or Mounjaro. Individual responses to GLP-1 agonists vary, and treatment should be personalized based on medical history, side effects, and health goals.